RE:RE:RE:RE:RE:The Data Yes we definitely need a bit more data in the next readout we will see if the trend keeps up, then we know we are on track for sure. So far CR's are going up. From November until now we see an improvement and looking at 360 days data and 450 days data in overall group on evaluable patients.
360 days. 450 days
November 4 CR out of 18 4 CR out of 16
4PR. 2PR
April 2022 5 CR out of 20 5 CR out of 20
3 PR. 2 PR
If the PR patients turn out to be CR at 450 days then we would jump to 7 out of 20 and 35% CR at 15 months. Given the fact that many anomalies in the initial group of 12, this would be amazing going forward especially if we see increasing CR after maintenance treatment at day 270 (90 days after treatment). All IMO. Certainly we need more data, but sell off was definitely not warranted and I think we should hopefully be trading back up and above previous high soon enough. GLTA
Infinity wrote: Enrique, That is a fairly accurate statement. Did not realise that the Data included 5 patients who were removed from the study, this completely makes any statistical conclusion skewed. The only way to draw meaningful conclusions would be to increase the sample size. We need more Patients in the study. One way to enroll more patients is to offer PDT as an option even before trying BCG. Considering the side effects are minimal and manageable, this could potentialy Fast Track the Clinical study. Getting FDA and Health Canada to go along with this requires lot of Input and Guidance from the Medical Advisory Board.... If you are looking purely from the point of benefits to the Patient, this is a very viable alternative.